Chronic Lymphocytic Leukemia
This fact sheet reviews the incidence and survival statistics of chronic lymphocytic leukemia.
Economic Evaluation of Obinutuzumab in Combination With Chlorambucil in First-line Treatment of Patients With Chronic Lymphocytic Leukemia in SpainSeptember 29, 2016
[ClinicoEconomics and Outcomes Research] This research examines the cost-effectiveness of obinutuzumab in combination with chlorambucil (GClb) versus rituximab plus chlorambucil (RClb) in the treatment of previously untreated chronic lymphocytic leukemia.
Assessment of minimal residual disease (MRD) improves the prediction of progression-free survival benefit in patients with CLL who achieve either a complete response or a partial response PR.
The US Food and Drug Administration has approved ofatumumab in combination with fludarabine and cyclophosphamide for the treatment of relapsed chronic lymphocytic leukemia (CLL).
Treatment with ibrutinib is associated with a high overall response rate in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and 17p deletion.
Patients with chronic lymphocytic leukemia (CLL) who discontinue TKI therapy due to toxicity can successfully be treated with an alternate TKI.
Ibrutinib treatment for chronic lymphocytic leukemia with the deletion of chromosome 17p (del17p CLL) increases the percentage of patients alive at 30 months over other therapies for del17p CLL.
New research indicates that rituximab maintenance therapy can extend progression-free survival in patients with chronic lymphocytic leukemia achieving at least a partial response to induction therapy with rituximab and chemotherapy.
Prognostic Index Will Improve Clinical Practice Management of Patients With CLL and in Clinical TrialsJune 10, 2016
An international consortium devised an international prognostic index for chronic lymphocytic leukemia (CLL-IPI) that combines genetic, biochemical, and clinical parameters into a prognostic model to enable more targeted management of patients with CLL.
The US FDA has granted Priority Review to ofatumumab used in combination with fludarabine and cyclophosphamide for the treatment of chronic lymphocytic leukemia.
Hair and nail abnormalities are commonly associated with the Bruton tyrosine kinase inhibitor ibrutinib.
Immunotherapeutic Agent Blocks Protein-Protein Interaction That Supports Chronic Lymphocytic Leukemia Growth and MetastasisJanuary 11, 2016
Wnt5a protein acts on a pair of tumor-surface proteins to accelerate the proliferation and spread of CLL. These effects of Wnt5a were blocked by a humanized monoclonal antibody called cirmtuzumab, according to a recent study.
Improvements were observed in progression-free survival, overall survival, and response rate for ibrutinib usage.
Idelalisib With Bendamustine and Rituximab Superior to Bendamustine and Rituximab alone for Relapsed/Refractory CLLDecember 10, 2015
For patients with relapsed/refractory CLL, the addition of idelalisib to bendamustine and rituximab can prove more beneficial than the latter two drugs alone, recent study data suggest.
Treatment with venetoclax monotherapy may be a viable option for some high-risk patients with relapsed/refractory chronic lymphocytic leukemia.
The high cost of for first-line oral targeted therapies for chronic lymphocytic leukemia needs to be addressed, based on model data examining CLL prevalence and patient affordability.
ONA presents an exclusive report on the initial findings on the safety profile of ibrutinib in asymptomatic patients with CLL, as presented at the International Workshop on Chronic Lymphocytic Leukemia.
Eight of 14 patients in the first clinical trial of personalized cellular therapy for chronic lymphocytic leukemia (CLL) responded to the therapy, with some complete remissions continuing beyond 4.5 years.
Two new targeted treatments slow progression of chronic-lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma.
A new meta-analysis of 26 factors has resulted in an internationally applicable prognostic index for patients with chronic lymphocytic leukemia, according to study results presented at 2015 ASCO Annual Meeting.
[Blood and Lymphatic Cancer: Targets and Therapy] The article discusses the history, use, and evolution of rituximab in the treatment of CLL and examines the next generation CD20 antibodies ofatumumab and obinutuzumab.
Study identifies reasons for ibrutinib discontinuation in patients with chronic lymphocytic leukemiaFebruary 27, 2015
About 10% of patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib discontinued their therapy due to disease progression during clinical studies.
The ASCO has announced that the transformation of treatment for chronic lymphocytic leukemia (CLL) is its Cancer Advance of the Year.
Genentech announced that the FDA has approved the sBLA for Gazyva (obinutuzumab) in combination with chlorambucil chemotherapy in patients with previously untreated chronic lymphocytic leukemia (CLL).
A new correlation discovered between specific molecular disease features and subgroups of patients with different prognoses could make identification of chronic lymphocytic leukemia (CLL) prognosis at the time of diagnosis possible.
A new study has discovered how resistance develops in patients taking ibrutinib, a new and highly effective drug for the treatment of chronic lymphocytic leukemia.
A new chemotherapy drug being investigated for its potency against two types of cancer was found to be effective in about one-third of the participants in a phase I study.
A German study of a new drug therapy for chronic lymphocytic leukemia (CLL) was lauded for including elderly persons who had other, coexisting health issues. An accompanying editorial noted that the study population more accurately represented patients with CLL.
A German study of a new drug therapy for chronic lymphocytic leukemia was praised because the majority of the patients enrolled were elderly and had other, coexisting health issues.
Approval of ibrutinib (Imbruvica) has been expanded to include people with chronic lymphocytic leukemia.
- Novel Colonoscopy Prep Is Poised to Improve Screening Rates for Colon Cancer
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- HIIT Improves Cardiorespiratory Fitness in Patients With Resectable NSCLC
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Recurrence Score Appears To Be Driving Personalized Treatment for Breast Cancer
- Smoking-related Cancer Deaths Highest in Southern United States
- Study Suggests More Men With Prostate Cancer Would Choose Active Surveillance if it Were Offered
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|